Key result
A selective EP4 agonist (ONO AE1-329) potently inhibited platelet aggregation and in vitro thrombus formation, suggesting EP4 receptor activation as a novel antithrombotic strategy.
Why the study?
Does EP4 receptor activation inhibit platelet aggregation and thrombus formation in human platelets?
Population
Human platelets
Comparison
Selective EP4 agonist (ONO AE1-329) vs null
Design
Preclinical
Authors
Loading...
EP4 agonism merits human platelet studies; leaves open clinical antithrombotic translation.
Does EP4 receptor activation inhibit platelet aggregation and thrombus formation in human platelets?
EP4 receptor activation potently inhibits platelet aggregation and thrombus formation, suggesting a potential novel antithrombotic strategy.
Philipose et al. (2010) studied this question. EP4 agonist (ONO AE1-329) vs. Control / EP4 antagonist was evaluated on Platelet aggregation and thrombus formation. A selective EP4 agonist (ONO AE1-329) potently inhibited platelet aggregation and in vitro thrombus formation, suggesting EP4 receptor activation as a novel antithrombotic strategy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: